Overview of Co-Enac Hexal

What is Co-Enac Hexal? (Overview)

Property	Description
Active Ingredients	Enalapril maleate and Hydrochlorothiazide
Form	Oral tablet
Pharmacological Class	ACE Inhibitor/Thiazide Diuretic Combination
Common Use	Treatment of essential hypertension (high blood pressure)
Availability	Prescription only

Co-Enac Hexal is a prescription medication formulated as a fixed-dose combination (FDC) therapy to manage essential high blood pressure, also known as hypertension. The medication is a specific formulation of two established antihypertensive agents that work together to lower blood pressure: enalapril maleate, an Angiotensin-Converting Enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic.

This specific dual composition is widely recognized and frequently recommended in clinical guidelines for its additive blood pressure-lowering effect. This type of FDC regimen is typically reserved for patients whose blood pressure is not adequately controlled when using either component alone, or for those who have been successfully transitioned to the combination dosage using the individual medicines. The combination targets two key mechanisms of action to achieve better overall blood pressure control.

The pairing of an ACE inhibitor with a diuretic is supported by pharmacological studies for addressing hypertension and is a common strategy in treating the condition. The diuretic component helps the body eliminate excess fluid and salt, which can complement the blood vessel-relaxing action of the ACE inhibitor, thus contributing to greater efficacy and utility in clinical settings.

Regulatory References

MedlinePlus Drug Information on Enalapril and Hydrochlorothiazide

What side effects are possible with Co-Enac Hexal?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics for Co-Enac Hexal, as classified by regulatory authorities (e.g., EMA, FDA).

Frequency-Classified Adverse Reactions

The safety profile is formally categorized by the likelihood of occurrence:

Very Common (ge 1/10): Dizziness, cough, blurred vision, nausea, and asthenia (weakness).
Common (ge 1/100 to < 1/10): Headache, syncope (fainting), depression, hypotension (low blood pressure) including orthostatic effects, diarrhoea, abdominal pain, fatigue, and chest pain.
Uncommon (ge 1/1,000 to < 1/100): Palpitations, pancreatitis, renal dysfunction, and impotence.
Rare (ge 1/10,000 to < 1/1,000): Agranulocytosis, hepatic failure, hepatic necrosis, jaundice, and Stevens-Johnson syndrome.

System-Organ Classes and Serious Reactions

Adverse effects are formally grouped by affected systems, including Vascular Disorders, Renal and Urinary Disorders, Metabolism and Nutrition Disorders, and Dermatological Reactions. Specific, serious adverse reactions identified in regulatory documents include Angioedema (swelling of the face, extremities, or throat, which may be fatal) and Acute Renal Failure.

Population-Specific Safety Constraints

The medication is subject to mandatory regulatory safety restrictions for specific groups:

Pregnancy: It is contraindicated due to the risk of injury or death to the developing fetus.
Severe Renal Impairment (Creatinine Clearance le 30 mL/min): The combination is contraindicated.
Severe Hepatic Impairment or Cholestasis: Use is contraindicated.

Regulatory documents also state that the risk of symptomatic hypotension is highest shortly after treatment initiation or following a dose increase, especially in patients with existing volume depletion. The combination is restricted from use with aliskiren in patients with diabetes or renal impairment and with Sacubitril/Valsartan due to heightened angioedema risk.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Co-Enac Hexal (Enalapril maleate and Hydrochlorothiazide) overdose documents severe physiological consequences arising from the combination’s effects. Overdosage is primarily characterized by excessive hypotension (severely low blood pressure), often leading to dizziness, fainting (syncope), and changes in heart rhythm (tachycardia or bradycardia). Other documented clinical signs include nausea, vomiting, and neurological effects such as confusion or stupor.

Severe outcomes documented in official labeling can include circulatory shock, acute renal failure (evidenced by oliguria or anuria), and critical electrolyte imbalances such as hyponatremia or hypokalemia. Seizures and trouble breathing are also listed as potential severe manifestations.

When to Seek Immediate Medical Attention: Urgent medical attention must be sought immediately if the patient exhibits life-threatening signs of severe toxicity, including collapse, having a seizure, being unresponsive, or experiencing severe trouble breathing. In all cases of suspected overdose, the medication should be discontinued and a Poison Control Center should be consulted for guidance. Treatment is symptomatic and supportive, requiring close hospital observation and laboratory monitoring of electrolytes and renal function. No specific antidote is known, though the Enalaprilat component is removable by hemodialysis. Elderly and volume-depleted patients are noted to be particularly susceptible to severe hypotensive effects.

Therapeutic Uses of Co-Enac Hexal

What Co-Enac Hexal Treats: Main Uses and Benefits

The core use for this combination is commonly used for managing essential hypertension, which are conditions characterized by periods of heightened symptoms (i.e., persistently elevated blood pressure). It is generally applied when blood pressure is not adequately controlled by a single-agent therapy, such as enalapril alone. This therapeutic approach helps to manage symptoms related to systemic imbalance that create noticeable physiological strain, which may be part of symptomatic management requiring additional support.

This dual-action medication is relevant for easing symptom clusters that may become intense or disruptive by simultaneously addressing both high vascular resistance and excess bodily fluid, thus supports general well-being. The combination is used for managing essential hypertension in patients whose conditions require addressing both high vascular resistance and fluid imbalance. Furthermore, the fixed-dose format may assist with the continuity of long-term management.

“The combination supports the patient in managing long-term well-being, addressing the chronic physiological strain caused by sustained high pressure.”

The combination assists with maintaining functional stability by supporting the patient during symptoms linked to organ-specific functional stress caused by chronic high pressure.

Quick Fact: Relief for Persistent Elevated Blood Pressure

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Co-Enac Hexal

Co-Enac Hexal (Enalapril maleate and Hydrochlorothiazide) is restricted to use in adult patients with essential hypertension whose condition is not adequately controlled by enalapril alone. Eligibility is strictly defined by regulatory documents, which establish several absolute prohibitions and restrictions.

Absolute Contraindications (Must Not Use)

Contraindicated Population/Condition	Restriction Basis
Pregnancy (2nd and 3rd trimesters)	High risk of fetal harm or death
History of Angioedema	Linked to prior use of any ACE inhibitor
Severe Organ Impairment	Severe renal impairment (CrCl le 30 mL/min) or severe hepatic impairment
Hypersensitivity	Allergy to the active components, any other ACE inhibitor, or sulfonamide-derived drugs
Concomitant Sacubitril/Valsartan	Prohibited use within a 36-hour period

Age and Conditional Restrictions

Use is not recommended in children and adolescents under 18 years because safety and efficacy have not been established. In patients with moderate renal impairment, use is restricted and generally requires successful individual titration of the components prior to starting the combination. Use during lactation is generally not recommended, particularly in the immediate postpartum period.

What should I know about interactions with other medicines?

Co-Enac Hexal contains enalapril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic). Due to its components, this medicine can interact with several other drugs and substances, necessitating careful consideration and monitoring by your healthcare provider.

Medications with Major Interaction Risk

Certain combinations should be avoided or used with extreme caution due to a significant risk of serious adverse effects, including dangerously low blood pressure or severe allergic reactions (angioedema) or hyperkalemia (high potassium levels):

Sacubitril/Valsartan (used for heart failure): Do not take Co-Enac Hexal within 36 hours of taking this combination.
Aliskiren (in diabetic patients): Avoid simultaneous use due to increased risk of hyperkalemia and kidney problems.
Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene) and Potassium supplements/salt substitutes containing potassium.

Medications Requiring Close Monitoring

The following medicines may require a dose adjustment or increased clinical monitoring when taken with Co-Enac Hexal:

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Such as ibuprofen or naproxen, which can reduce the blood pressure-lowering effect and increase the risk of kidney problems.
Lithium: Clearance of lithium may be reduced, potentially leading to toxic levels.
Other antihypertensives: The combination with other blood pressure-lowering medicines may result in an additive effect, causing excessive drops in blood pressure.
Tricyclic antidepressants, antipsychotics, or barbiturates: May increase the risk of a sudden drop in blood pressure when standing up (orthostatic hypotension).

Other Interactions

Alcohol: Consumption can enhance the blood pressure-lowering effect, increasing the risk of dizziness or fainting. Limit intake while on this medication.
Corticosteroids: May oppose the diuretic effect of hydrochlorothiazide.

Always inform your doctor or pharmacist about all prescription and non-prescription medicines, vitamins, and herbal products you are taking.

Mechanism of Action

Co-Enac Hexal is a fixed-dose combination comprising enalapril and hydrochlorothiazide. Its mechanism involves two distinct pharmacological targets. The prodrug enalapril is hydrolyzed in vivo to its active metabolite, enalaprilat, which acts as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), primarily located on the vascular endothelium and in the renal capillaries.

Enalaprilat Mechanism

Inhibition of ACE prevents the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor octapeptide angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS). Reduced plasma angiotensin II levels diminish the signaling cascade for vasoconstriction and suppress the release of aldosterone from the adrenal cortex. This results in systemic vasodilation and a reduction in renal sodium and water reabsorption. Furthermore, ACE inhibition decreases the degradation of bradykinin, an endogenous peptide that promotes vasodilation, which amplifies the anti-constrictive effects.

Hydrochlorothiazide Mechanism

Hydrochlorothiazide acts on the kidney's distal convoluted tubule as a diuretic. It functions as an inhibitor, blocking the Na^+/ Cl^- symporter (NCC) on the apical membrane of the tubule cells. This molecular interaction prevents the reabsorption of sodium and chloride ions from the tubular lumen into the cell. The subsequent increase in luminal osmotic load, due to retained Na^+ and Cl^-, reduces the passive reabsorption of water, leading to an increased systemic excretion of salt and water. This diuretic action results in a decrease in total extracellular fluid volume and plasma volume, modulating systemic fluid homeostasis and consequently lowering peripheral vascular resistance.

Dosage and Administration Information

Co-Enac Hexal is an oral medication administered for the long-term management of essential hypertension. The fixed-dose combination (FDC) tablet must be swallowed whole and should not be split or crushed, which is a handling constraint for this formulation. The established adult regimen is one tablet once daily, a schedule designed to maintain consistent blood pressure control.

The FDC is reserved for patients whose blood pressure is not adequately controlled by monotherapy with either component, or as replacement therapy after successful titration on the individual agents. It is not indicated for use as initial therapy.

For administration timing, the tablet may be taken with or without food. A critical procedural condition is the management of pre-existing diuretic use: any prior diuretic therapy must typically be discontinued for two to three days before initiating Co-Enac Hexal to mitigate the risk of symptomatic hypotension.

Official labeling specifies important population-based restrictions. The medicine is not recommended for use in the pediatric population because safety and efficacy have not been established. Furthermore, its use is prohibited in patients with severe renal impairment (creatinine clearance 30 mL/min), defining a functional limit for administration. Should a dose be missed, the instruction is to skip the missed dose and resume the regular once-daily schedule the following day, rather than taking an extra tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Study Findings:

Research has evaluated the compound's study mechanism, which involves inhibiting the Angiotensin-Converting Enzyme (ACE). Overall, studies have explored the compound, a fixed-dose combination of an ACE inhibitor (enalapril) and a diuretic (hydrochlorothiazide), in various research models.

Efficacy and Outcomes Research

One randomized controlled trial (RCT) reported that patients who received the compound showed a difference in the measured endpoint (blood pressure reduction) within a defined period. In the trial, researchers examined whether the difference in outcomes in participants receiving the compound differed from the difference in the placebo group. The researchers note that follow-up studies are exploring the maintenance of these findings, with some evidence suggesting the antihypertensive effect was sustained for at least 24 hours.

Other research has focused on studies that explore the measured difference in pain perception in animal models. These studies utilized specific biomarkers to measure potential differences.

While results from some studies indicated a difference in outcomes, one smaller study noted no statistically significant difference in the primary endpoint between the compound group and the control group.

Pharmacokinetics and Safety Profile

Studies of the compound in combination with another agent have been performed in a laboratory setting. Research examined whether the combination affected absorption. Clinical studies have shown that the combination may counterbalance the potassium loss associated with the diuretic component alone.

Excluded Populations in Clinical Trials

Studies excluded individuals with significant liver issues. It is not yet established whether the research response is similar in this group. Research has evaluated whether the combined treatment results in a different outcome compared to monotherapy. Studies are ongoing to characterize the full risk profile, including the reported incidence of cough and gastrointestinal discomfort as common adverse experiences in clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Co-Enac Hexal (FAQ)

Q: Is Co-Enac Hexal the same as standard Enalapril?

No. According to official product information, Co-Enac Hexal is a fixed-dose combination medication that contains two active ingredients: enalapril and hydrochlorothiazide (a diuretic). Standard enalapril contains only enalapril. The combination is typically reserved for patients whose blood pressure is not controlled by monotherapy with a single component.

Q: Can Co-Enac Hexal affect sleep patterns?

Official documents list adverse effects such as insomnia (difficulty sleeping) and other sleep disorders as possible, though uncommon or rare, reactions to the medication.

Q: Does Co-Enac Hexal have any known interactions with salt substitutes?

Yes. Salt substitutes often contain potassium chloride. The enalapril component of the medicine can contribute to high potassium levels in the blood, a condition called hyperkalemia. The use of potassium-containing salt substitutes in conjunction with this medication is an interaction that necessitates careful clinical consideration.

Q: Can Co-Enac Hexal be used to treat swelling or fluid retention?

The official indication for Co-Enac Hexal is the treatment of essential hypertension (high blood pressure). While it contains a diuretic component that helps manage fluid, its use is specifically approved for blood pressure control that is not adequately managed by a single ingredient alone.

Q: What is the expected length of time for taking Co-Enac Hexal?

The drug is indicated for the long-term management of essential hypertension. This indicates that treatment is intended for the sustained, long-term management of the chronic condition.

Q: Does Co-Enac Hexal cause tiredness or low energy?

Yes. Official adverse reaction reports list tiredness (fatigue) and weakness (asthenia) as very common side effects of the combination medicine. This information is classified in the official safety profile documents.

Q: Is it normal to feel dizzy after starting Co-Enac Hexal?

Dizziness is listed as a very common side effect in the official safety profile. Furthermore, the risk of low blood pressure (hypotension) and associated dizziness is generally highest shortly after treatment initiation.

Q: Are there any common skin reactions associated with Co-Enac Hexal?

Yes. Official documents note skin rash as a common adverse reaction. Separately, the hydrochlorothiazide component is associated with a small, long-term increased risk of non-melanoma skin cancer, which emphasizes the need for protective measures against sun exposure.

Q: Does the consumption of alcohol interact with Co-Enac Hexal?

Yes. According to regulatory documents, alcohol consumption may enhance the medicine's blood pressure-lowering effect. This can increase the risk of symptoms like dizziness or fainting due to a sudden drop in blood pressure when standing up (orthostatic hypotension).

Q: Is Co-Enac Hexal available in different strengths?

Yes. Factual information provided by regulatory agencies confirms that the medication is available in fixed-dose combination tablets with at least two different strengths of its active ingredients, enalapril and hydrochlorothiazide.

Q: Does Co-Enac Hexal have a generic alternative?

Yes. Official approval history indicates that the combination of enalapril maleate and hydrochlorothiazide is available as a generic medicine, in addition to various brand names.

Q: Are there any long-term health concerns associated with Co-Enac Hexal use?

While the drug is used for long-term management, regulatory documents specify that ongoing monitoring is required. This monitoring includes checking for changes in kidney function, detecting electrolyte imbalances, and managing the small increased risk of non-melanoma skin cancer linked to the hydrochlorothiazide component.

Q: Why might a doctor switch a patient from a different medication to Co-Enac Hexal?

The medication is officially reserved for use in patients whose blood pressure is not adequately controlled by taking either enalapril or hydrochlorothiazide alone. It is also used as a convenient replacement therapy after a patient has successfully had their dose adjusted on the individual components.

Q: What is the expected duration of the effects of one tablet of Co-Enac Hexal?

Studies and official information indicate that the antihypertensive effect of the medicine is generally sustained for up to 24 hours. This duration supports its intended use as a once-daily dosing medication.

Q: What evidence exists regarding the use of Co-Enac Hexal in specific patient groups, such as those with diabetes?

Regulatory warnings mention specific precautions for patients with diabetes. These include advising against the co-administration of the medicine with aliskiren, and noting that thiazide diuretics may influence glucose (sugar) levels.

Q: Can the combination of ingredients in Co-Enac Hexal cause an increased need to urinate?

Yes. The hydrochlorothiazide component is classified as a diuretic, or 'water pill.' Its function is to increase the body's excretion of salt and water, which results in an expected increase in the need to urinate.

Q: Do official sources list vision changes as a possible side effect of Co-Enac Hexal?

Yes. Official sources list blurred vision as a common adverse effect. Official warnings also describe rare, serious vision changes, such as acute transient myopia or acute angle-closure glaucoma, which are conditions requiring immediate medical evaluation.

Q: Is there information on patient eligibility for Co-Enac Hexal based on race or ethnicity?

Regulatory documents note that ACE inhibitors, like the enalapril component, have been reported to cause a higher rate of angioedema (a rare but serious swelling reaction) in Black patients compared to non-Black patients.

Q: Does Co-Enac Hexal have restrictions regarding use before surgery?

Yes. If surgery requiring anesthesia is planned, it is important for the healthcare team to be informed ahead of time. This is because the medicine may cause sudden low blood pressure during anesthesia.

Q: Is there a risk of electrolyte imbalance mentioned in the official literature for Co-Enac Hexal?

Yes. Due to the action of the hydrochlorothiazide component, official documents state there is a risk of developing electrolyte imbalances. This refers to changes in the levels of minerals like potassium, sodium, and chloride in the blood.

How should Co-Enac Hexal be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines define precise conditions for storing and discarding Co-Enac Hexal (enalapril maleate/hydrochlorothiazide) to ensure product stability and safety.

Requirement	Regulatory Statement
Temperature	Store at controlled room temperature, generally between 15 C and 30 C (59 F to 86 F), and do not freeze.
Protection	Keep the medicine in its original container, tightly closed, and protect it from excess heat, light, and moisture.
Child Safety	Mandatory to keep the medication out of the sight and reach of children.
Disposal	The preferred method is using a community drug take-back program. If unavailable, tablets should be mixed with an undesirable substance (e.g., used coffee grounds, dirt), sealed in a container, and placed in household trash.
Environmental Rule	Do not dispose of the tablets by flushing them down the toilet or pouring them down a sink.

Co-Enac Hexal